Key Points Definium Therapeutics reported positive Phase 3 results for DT120, its investigational LSD-based treatment for generalized anxiety disorder, or GAD. A single DT120 dose…
August 11, 2026
AC Immune Speeds Toward a Potential Parkinson’s Breakthrough with FDA Fast Track Status
Key Points AC Immune received FDA Fast Track designation for ACI-7104, its investigational active immunotherapy for early Parkinson’s disease. The company also received FDA clearance…
Key Points Shattuck Labs reported favorable Phase 1 results for SL-325, including a positive safety profile, low anti-drug antibody incidence, and durable DR3-pathway blockade. The…
Key Points Scholar Rock said the FDA review of apitegromab for spinal muscular atrophy is progressing with the company’s second fill-finish manufacturing facility. The company…
Key Points Silence Therapeutics reported $72.1 million in cash and cash equivalents at the end of Q2 2026. Net loss narrowed to $12.3 million, or…
Key Points Verastem Oncology reported $25.1 million in Q2 2026 net product revenue from AVMAPKI FAKZYNJA CO-PACK, up 34% sequentially from $18.7 million in Q1….
Ahead of Nuvation Bio’s (NYSE: NUVB) second-quarter results, investors were looking for evidence that the company’s strong first quarter represented the beginning of a sustainable…
August 06, 2026
Vistagen’s Repeat-Dose Study Supports Fasedienol’s Potential in Social Anxiety Disorder
Key Points Vistagen reported topline results from an exploratory Phase 2 repeat‑dose study of fasedienol nasal spray for the acute treatment of social anxiety disorder….
Key Points Citius Oncology, Inc. reports accelerating commercial momentum for LYMPHIR, its FDA‑approved treatment for cutaneous T‑cell lymphoma (CTCL). New U.S. institutions ordering LYMPHIR rose…
Key Points BriaCell Therapeutics Corp. received FDA clearance to begin a clinical study of Bria-PROS in prostate cancer. The company is developing Bria-PROS as a…
August 04, 2026
DarioHealth Expands Its Provider-Backed Cardiometabolic Platform with New Women’s Health and Sleep Programs
Key Points DarioHealth Corp. is broadening its digital cardiometabolic platform with new women’s health and sleep-focused services. The company is adding provider-backed care and clinical…
Key Points Rhythm Pharmaceuticals, Inc. reported preliminary Phase 2 data for RM-718, its investigational MC4R agonist. The early results support continued development of RM-718 in…